Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

9.096 -0.174 (-1.87%)
Streaming Delayed Price Updated: 10:47 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 171,151
Open 9.140
Bid (Size) 9.070 (300)
Ask (Size) 9.100 (500)
Prev. Close 9.270
Today's Range 9.000 - 9.440
52wk Range 3.455 - 11.24
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
From Verastem Oncology
Via Business Wire

Performance

YTD
+40.2%
+40.2%
1 Month
-0.6%
-0.6%
3 Month
-7.4%
-7.4%
6 Month
+61.3%
+61.3%
1 Year
+94.4%
+94.4%

More News

Read More
News headline image
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Proposed Public Offering of Common Stock
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
Verastem Inc (NASDAQ:VSTM) Reports Q3 2025 Revenue Beat Amid Widened Loss ↗
Via Chartmill
News headline image
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
From Verastem Oncology
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
From Verastem Oncology
Via Business Wire
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Via FinancialNewsMedia

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 9.096
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 12/16/25 10:47 AM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 407.37M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 407M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.